Brind.
  1. LIXTE Biotechnology Holdings, Inc. has announced recent scientific developments regarding its drug candidates, including inhibitors targeting protein phosphatase 2A.

A study led by Amir Jazaeri validated the efficacy of LIXTE's compound LB100.

1 report, 0 independent Updated Jul 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

A study led by Amir Jazaeri validated the efficacy of LIXTE's compound LB100.

Keep exploring

Part of

LIXTE Biotechnology Holdings, Inc. has announced recent scientific developments regarding its drug candidates, including inhibitors targeting protein phosphatase 2A. All 2 developments

Coverage

Newest first; wire copies grouped
  • Unknown outlet